Independent Survey Results Presented at the 5th Global Congress on Prostate Cancer (PROSCA) Indicate Untapped Market Potential for SelectMDx
NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07:00 CEST, July 3 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that results from an independent urology survey identify lack of knowledge on the new generation biomarker tests for Prostate Cancer . Survey data were presented on June 28 th at the fifth Global Congress on Prostate Cancer in Lisbon, Portugal.
In his keynote presentation "Biomarkers in 2017," Prof. Nicolaas Lumen, MD, PhD, Head of Clinic Urology at University Hospital Gent, Belgium, reported that almost half of urologists do not recommend any diagnostic biomarker tests to patients. Survey data identified that the limited utilization figures result from a lack of familiarity with the clinical advances offered by new generation tests. Of the 300 urologists participating in Dr. Lumen's survey, biomarker test utilization would nearly double (to 90%) if the urologists had access to a test with a negative predictive value (NPV) of 98% for clinically significant cancer.
"The results of this survey highlighted that urologists are more familiar with older biomarker tests like PCA3 that do not have such a high NPV for significant prostate cancer," said Prof. Dr. Lumen. "The new generation biomarker tests are more accurate to identify clinically significant prostate cancer and are valuable tools for further risk assessment to determine whether or not to proceed with biopsy."
"Dr. Lumen's survey clearly identifies a significant untapped market for our SelectMDx for Prostate Cancer test." said Dr. Jan Groen, CEO of MDxHealth , "SelectMDx is an affordable non-invasive liquid biomarker test with a 98% NPV for Gleason score 7 or greater prostate cancer and is available for use in Europe and the US."
A recording of Dr. Lumen's survey data presentation and his full lecture will be available on www.ProstateMDx.org .
About SelectMDx for Prostate Cancer
Of the more than 2 million prostate biopsies performed each year in the US and Europe, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harboring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce diagnostic procedures, such as MRI and invasive prostate biopsies, by approximately 50%, thereby reducing healthcare costs.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter.com/mdxhealth , facebook.com/mdxhealth and linkedin.com/company/mdxhealth .
For more information:
Shalon Roth, EVP Corporate Communications MDxHealth +44 (0)7393 906278 shalon.roth@mdxhealth.com
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx , AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
Attachments:
